Samsara Vision today announced that Jason Herod, Vice President Commercial, International Markets, is promoted to Chief Commercial Officer, effective August 15, 2024. Samsara Vision is a privately held specialty medical device company focused on intraocular ophthalmic devices that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders.
Jason Herod joined Samsara Vision in August 2021 and brings over 24 years of ophthalmic medical device, pharmaceutical, and OTC business experience. Now based in Geneva, Switzerland, Jason has lived and worked in Canada, the United States, and Czech Republic, holding many roles of increasing responsibility in sales, sales management, country, regional and global marketing, country general management, and as the Franchise Head for Europe, Middle East, Africa, Russia for Alcon.
In his role as Chief Commercial Officer, Jason will continue to support the European rollout of the SING IMT® (Smaller-Incision New-Generation Implantable Miniature Telescope), Samsara Vision’s flagship, intraocular telescope (IOT) for older adults living with late-stage, age-related macular degeneration (AMD). He will also work closely with other members of the company’s C-suite to advance availability of the SING IMT in other global markets and provide oversight for the company’s ongoing U.S. clinical trial.
“When Jason joined Samsara Vision three years ago after spending much of his career focused on eye health with Alcon and Allergan, I was immediately impressed by his strategic acumen and team building ability. His leadership contributed to our success earning a CE Mark and launching the SING IMT in 17 EU countries to date,” said Thomas Ruggia, President and CEO of Samara Vision. “I look forward to working with Jason even more closely as the Chief Commercial Officer as we build our business in China, APAC, Australia, and Latin America.”
“I am delighted and grateful to be named the CCO at such an important and exciting moment in our company’s history. Our innovative approach to addressing the so-called ‘non-preventable’ blindness caused by late-stage AMD has led to more and more stories from patients telling us about how their improved vision helps them to reengage with their families and activities they love following their SING IMT procedure and therapy,” said Jason Herod, Chief Commercial Officer. “I look forward to working with Tom and the rest of the Samsara Vision team to bring our remarkable technology to global markets around the world.”
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!
